Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trader J's Inner Circle -- Ignore unavailable to you. Want to Upgrade?

To: Trader J who wrote (2787)	12/30/1998 1:45:00 AM
From: RAYS	Read Replies (1) \| Respond to of 56535

Thanks for sharing Trader J: Can I ask you how much $$$$ you started with ? Just looking for hope! Anyway-Congratulations! that's a tidy sum no matter how much you had to start. Thanks for the anti-greed reminder!

To: Trader J who wrote (2787)	12/30/1998 2:39:00 AM
From: BANCHEE	Respond to of 56535

Trader J Here is something from BIKR thread on SI Message 7021970 Hope wife & daughter are doing fine. Nite, Banchee

To: Trader J who wrote (2787)	12/30/1998 7:54:00 AM
From: Dub Brown	Read Replies (1) \| Respond to of 56535

Cutting losses..Thanks for reinforcing the importance of money management. Watched as XYLN went from 22 to 14 also BMCS 56 to 43..cost me a ton!! Enjoy your thread, been following from the start! Thanks DB

To: Trader J who wrote (2787)	12/30/1998 9:47:00 AM
From: Buddy Smellgood	Read Replies (1) \| Respond to of 56535

ASCT NEWS: TraderJ: will this effect the buyout? This kind of looks like a buying opportunity. buddy WILMINGTON, Mass., Dec. 30 /PRNewswire/ -- Ascent Pediatrics, Inc. (Nasdaq: ASCT) today announced that it received a Not-approvable Letter from the FDA on its NDA for its acetaminophen extended release product Feverall Extended Release Sprinkles. In the letter, the FDA primarily referenced deficiencies relating to the manufacture and packaging of the product. Dr. Emmett Clemente, Chairman and Founder of Ascent commented, "The FDA letter was not unexpected based on a number of conversations with the FDA that have transpired over the past weeks. Most of the deficiencies listed in the Letter were previously communicated to Ascent and Ascent had been working with the FDA to address the FDA's concerns prior to the receipt of the Letter. We intend to amend the NDA to address the listed deficiencies and, subject to ultimate FDA approval, we do not anticipate, at this time, that the Not-approvable Letter will have a material effect on the product introduction." Ascent Pediatrics, Inc. is a drug development and marketing company focused exclusively on the pediatric market. The Company's strategy is to address the unmet needs of children through the development of differentiated, proprietary products based on approved compounds with well-known clinical profiles. Ascent is developing a range of pharmaceuticals designed to improve upon currently available products for common pediatric illnesses through the application of its drug delivery and reformulation techniques. Investors are cautioned that this press release contains forward-looking statements that involve a number of risks and uncertainties. For this purpose, any statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "expects", "intends", "will" and similar expressions are intended to identify forward-looking statements. Information contained in these forward looking-statements is inherently uncertain, and actual performance and results may differ materially due to numerous factors, including but not limited to the following: capital needs and uncertainty of additional funding, the Company's early stage of development, history of operating losses and cumulative deficit, uncertainly relating to regulatory approval of the Company's products, including the Feverall Extended Release product referenced above, seasonality and variable operating results, dependence on new product development and acceptance, management of growth, dependence on third parties, inability to retain or attract customers due to competition and uncertainty in the healthcare industry. These factors are more fully described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 1997, under the caption "Management's Discussion and Analysis of Financial condition and Results of Operations -- Certain Factors That May Affect Future Results", which is incorporated herein by this reference. SOURCE Ascent Pediatrics, Inc.

To: Trader J who wrote (2787)	12/31/1998 1:01:00 AM
From: Mike McFarland	Respond to of 56535

Wow, that's terrific--I've mainly been goofing off this past week and have not kept up with the thread. As long as we are marking down our score for the year, I will say that I have not made up my mind whether I have any skill trading, I am pretty set on the idea that I've had some luck, but still have a lot to learn--and anybody seriously trading this year should have made a bundle, so my gain doesn't seem like so much. That said... my balance a year ago was 15k, I peaked out in August at 70k...bottomed out again in October at 30k...and now am at 44k. In an ira, so pretty happy about that. I traded one interenet-related stock for a twenty grand loss, I must have had some delusion about SoftQuad's xml expertise, what a fool I was--plus they have a games division and they did not get their Elmo cdrom out in time for Christmas, I sold off the last of my swebf months ago between $1/2 and $1, a real big bet gone bad. If anybody is interested in what got me started...GMGC, which I rode from around a buck to $5, sadly I got out too early on that one--it peaked around $14 and then fell back to around $5. Well, a little pat on the back, but I'm not taking myself to serious, I should have been in AMZN or AOL right? --Mike